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The study aimed to explore the role of ERBB3 in type 1 diabetes (T1D). We examined whether genetic
variation of ERBB3 (rs2292239) affects residual b-cell function in T1D cases. Furthermore, we examined
the expression of ERBB3 in human islets, the effect of ERBB3 knockdown on apoptosis in insulin-
producing INS-1E cells and the genetic and regulatory architecture of the ERBB3 locus to provide in-
sights to how rs2292239 may confer disease susceptibility. rs2292239 strongly correlated with residual
b-cell function and metabolic control in children with T1D. ERBB3 locus associated lncRNA (NON-
HSAG011351) was found to be expressed in human islets. ERBB3 was expressed and down-regulated by
pro-inﬂammatory cytokines in human islets and INS-1E cells; knockdown of ERBB3 in INS-1E cells
decreased basal and cytokine-induced apoptosis. Our data suggests an important functional role of ERBB3
and its potential regulators in the b-cells and may constitute novel targets to prevent b-cell destruction in
T1D.
© 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Type 1 diabetes (T1D) is amultifactorial diseasewith both genetic
and environmental determinants. Genome-wide association studies
(GWAS) have identiﬁed around 50 genetic loci that contribute to
disease susceptibility (Barrett et al., 2009; Onengut-Gumuscu et al.,
2015) (www.t1dbase.org) but the underlying mechanisms largely
remain unknown. Several studies identiﬁed association between
T1D and variations at chromosome 12q13 surrounding the ERBB3
gene. Originally, association with T1D was demonstrated for the
single nucleotide polymorphism (SNP) rs11171739, which maps be-
tween the RPS26 and ERBB3 genes (Burton et al., 2007). Most studies,
including a meta-analysis, identiﬁed the strongest association with
the single nucleotide polymorphism (SNP) rs2292239, located in
intron 7 of ERBB3 (Barrett et al., 2009; Onengut-Gumuscu et al., 2015;f Pediatrics, Herlev University
k.
. Pociot).
up are listed in the Appendix.
rved.Burton et al., 2007; Hakonarson et al., 2008; Todd et al., 2007; Keene
et al., 2012). Genetic variations in ERBB3 have also been used in
different model approaches to improve prediction of T1D (Winkler
et al., 2012; Bonifacio et al., 2014), autoimmunity (T€orn et al., 2015;
Brorsson and Pociot, 2015) and disease progression (Achenbach
et al., 2013; Andersen et al., 2013). Despite the convincing genetic
association of the ERBB3 region with T1D the functional implication
underlying this has not been explored in detail, although it has been
suggested that their most likely mechanism for affecting disease risk
would be through effects on gene expression (Keene et al., 2012).
ERBB3 is a member of the epidermal growth factor receptor
(EGFR) family with impaired tyrosine kinase activity. It forms het-
erodimers with other EGFR family members that do have kinase
activity thereby allowing activation of multiple signaling pathways
including the phosphoinositol 3-kinase/AKT survival/mitogenic
pathway. Increased ERBB3 expression plays an important role in the
progression of several tumour forms (Baselga and Swain, 2009).
Interestingly, the ERBB3 locus also overlaps with other autoimmune
disease loci such as psoriasis, rheumatoid arthritis, vitiligo and
alopecia.
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2.1. Patients
This cross-sectional study involved 18 pediatric centres world-
wide (De Beaufort et al., 2013). All children diagnosed with type 1
diabetes mellitus below 11 years of age and with diabetes duration
of at least 1 year, treated at these centres, were invited to partici-
pate. Of 1209 eligible children in 18 centres, 1133 (93.7%) children
(47.4% females; mean age: 8.0± 2 years; diabetes duration: 3.8± 2.1
years) participated and 1107 (91.6%) provided a blood sample for
HbA1c analysis and capillary blood spots for genetic analysis.
Genotyping was possible on 873 samples (79%). The children were
characterized for gender, age at diagnosis, diabetes duration,
HbA1c, insulin dose and insulin dose-adjusted HbA1c (IDAA1c)
(calculated as HbA1c þ 4 * insulin dose/kg/24 h) as a surrogate
marker for residual C-peptide and b-cell function (Max Andersen
et al., 2014). For all children, detailed descriptions of the insulin
regimens, episodes of severe hypoglycemia (seizures or loss of
consciousness in the past 3 months), and diabetic ketoacidosis
(DKA requiring hospital admissionwithin the past 12months) were
obtained. A centralized HbA1c measurement was performed by the
TOSOH® liquid chromatography (DCCT aligned, normal range:
4.4e6.3%; IFFC: 25e45 mmol/mmol).2.2. DNA extraction and genotyping
DNA was extracted from dried blood spots on ﬁlter paper using
the DNeasy kit (Qiagen, Hilden, Germany) following the manufac-
turer's instruction. The SNP, rs2292239 in intron 7 of the ERBB3
gene, as well as the rs2187668 and rs7454108 of the MHC region,
were genotyped using predesigned TaqMan® SNP Genotyping As-
says (Life Technologies, Carlsbad, CA, USA). The two MHC SNPs
were used to stratify for the HLA DR3/4 high-risk genotype (Barker
et al., 2008; Romanos and Wijmenga, 2009). Linear regression
models were used to test the association between metabolic con-
trol (HbA1c, insulin dose and IDAA1c) as dependent variables and
SNP genotypes as the descriptive variables. Comparison between
groups was performed using a two-tailed t test.2.3. Functional SNPs and cis-eQTLs
To identify SNPs associated with changes in expression (cis-
eQTLs) of ERBB3, we integrated data from multiple eQTL studies
(Stranger et al., 2012; Westra et al., 2013; GTEx Consortium, 2015).
GWAS SNPs (p-value 0.01) for T1D were retrieved from T1DGC
(Barrett et al., 2009) and linkage disequilibrium (LD) analysis was
performed using SNAP (Johnson et al., 2008). We used ENCODE
datasets (ChIP-Seq peaks, DNase I hypersensitivity peaks, DNase I
footprints) from UCSC genome browser (Rosenbloom et al., 2013)
(http://genome.ucsc.edu/) and RegulomeDB (Boyle et al., 2012) to
identify functional evidence associated with ERBB3 variants.2.4. Culture and treatment of human islets
Human islets were isolated from pancreata of four healthy organ
donors provided through the integrated islet distribution program
(IIDP) and cultured as described previously (Ardestani et al., 2014;
Schulthess et al., 2009). Islets were exposed to 2 ng/ml recombinant
human IL-1b (R&D Systems, Minneapolis, MN, USA), 1000 U/ml
recombinant human IFN-g (PeproTech, Rocky Hill, NJ, USA), and
1000 U/ml TNFa (R&D Systems) for 6e72 h.2.5. Culture and transfection of INS-1E cells
INS-1E cells were cultured as previously described (Fløyel et al.,
2014). Cells were transfected with 30 nM of siRNA. Lipofectamine
RNAiMAX (Life Technologies) was used as transfectant. Non-
targeting control siRNA (siCTRL) and siRNA against ERBB3
(siERBB3) were SmartPool siGENOME siRNAs (Dharmacon, Lafay-
ette, CO, USA). Two days post transfection cells were treatedwith or
without 150 pg/mL recombinant mouse IL-1b (BD Pharmingen, San
Diego, CA, USA) and 5 ng/mL recombinant rat IFN-g (R&D Systems)
for 24 h.
2.6. Non-coding RNAs within ERBB3 locus
NONCODE v4 database (Xie et al., 2014) was used to identify
lncRNAs present within the ERBB3 locus. We used StarBase v2.0 (Li
et al., 2014) to identify miRNA binding sites within ERBB3 30UTR
based on CLIP-Seq overlap (using selection criteria for target pre-
diction by at least two tools and 2 CLIP-Seq experiments).
Perturbation of miRNA binding within the 30UTR of ERBB3 was
predicted by miRdSNP (Bruno et al., 2012).
2.7. Expression of ERBB3 and its associated lncRNAs in human islets
and other tissues
For expression of ERBB3 and its associated lncRNAs across 14
human tissues, we leveraged publicly available Human BodyMap
(HBM) 2.0 RNAseq data (ENA archive: ERP000546) and NONCODE
v4 (Xie et al., 2014). Expression values were expressed as fragments
per kilobase of exon per million reads (FPKMs). The absolute value
of the Pearson correlation coefﬁcient was calculated for all pair-
wise comparisons of gene-expression values for ERBB3 and asso-
ciated lncRNAs. All statistical analyses were performed with Bio-
conductor in the R statistical environment (Gentleman et al., 2004).
Total RNA was isolated from human islets using TriFast™ (Peq-
lab, Erlangen, Germany) following the manufacturer's instructions.
cDNA was prepared using iScript™ cDNA synthesis kit (BioRad,
Hercules, CA, USA), except for the antisense lncRNA NON-
HSAG011351, where a gene- and strand-speciﬁc reverse transcrip-
tion was performed as described previously (Perocchi et al., 2007)
using iScript™ Select cDNA synthesis kit (BioRad). Quantitative
real-time PCR (qPCR) was performed on ERBB3, CTCF and three
lncRNAs (NONHSAG011348, NONHSAG011349 and NONHSAG011351)
using inventoried and custom-designed PrimeTime qPCR 50
Nuclease assays (Integrated DNA Technologies, Coralville, IA, USA)
and Brilliant III Ultra-Fast QPCR Master Mix (Agilent Technologies,
Santa Clara, CA, USA) with 10 ng/well of cDNA as template. Primer
sequences are provided in Supplementary Table S1. Expression was
represented by deltaCT method with GAPDH as the reference gene.
Additionally, expression of lncRNAs NONHSAG011348, NON-
HSAG011349, NONHSAG011351 and ERBB3 was also measured in
HapMap lymphoblastoid cell lines of individuals of European
descent (CEU, n ¼ 50) (Fløyel et al., 2014).
2.8. Western blotting
Human islets were washed with PBS and lysed in RIPA lysis
buffer containing 50 mM Tris-HCL pH 8.0, 150 mM NaCl, 1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS supplemented with 1X Pro-
tease- and Phosphatase-inhibitors (100X) (Pierce, Rockford, IL,
USA). INS-1E cells were lysed in M-PER Mammalian Protein
Extraction Reagent supplemented with Halt Protease & Phospha-
tase Inhibitor Cocktail (all from Pierce). Western blotting was per-
formed as previously described (Fløyel et al., 2014). Antibodies used
were anti-ERBB3 (12708, Cell Signaling, Danvers, MA, USA), anti-
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SigmaeAldrich, St. Louis, MO, USA), anti-GAPDH (ABS16, Millipore,
Billerica, MA, USA), anti-rabbit IgG (7074, Cell Signaling), and anti-
mouse IgG (7076, Cell Signaling).
2.9. Apoptosis
Apoptosis was determined using Cell Death Detection ELISA
(Roche, Basel, Switzerland) as previously described (Fløyel et al.,
2014). The activities of caspases 3 and 7 were measured by the
Caspase-GLO 3/7 assay (Promega, Madison, WI, USA) using 50 ml
Caspase-GLO reagent per well. Both assays were measured on a
M200-pro multiplate reader (Tecan, M€annedorf, Switzerland). Data
was calculated as fold over non-treated siCTRL-transfected cells.
3. Results
3.1. rs2292239 associates with residual b-cell function and
metabolic control
The T1D-associated SNP rs2292239 was signiﬁcantly associated
with IDAA1c (p-value ¼ 0.0067) and HbA1c (p-value ¼ 0.019) in a
recessive model corrected for gender, age at diagnosis and diabetes
duration (Table 1). The TTgenotype carriers had a lower IDAA1c and
a lower HbA1c compared to carriers of the GG and GTgenotypes. No
association to hypoglycemic events or DKAwas observed. HLA DR3/
DR4 heterozygosity was associated with lower age at diagnosis
(est. ¼ -0.45; p-value ¼ 0.007). The DR3/DR4 genotype did not
affect any measures of metabolic control. No signiﬁcant differences
in gender, age at diagnosis, disease duration, HbA1c, IDAA1c or
insulin dose were observed between the genotyped (984/1133) and
non-genotyped parts of the cohort.
3.2. rs2292239, rs3741499 and rs4759229 are putatively functional
To investigate how rs2292239 may confer disease susceptibility
we explored the genetic and regulatory architecture of the ERBB3
locus. SNPs that act as cis-eQTLs, overlap ENCODE regulatory fea-
tures and are in strong LDwith a known disease-associated SNP are
considered as functional SNPs (Schaub et al., 2012). rs2292239 has
been shown to act as cis-eQTL for ERBB3 in whole blood (Westra
et al., 2013; GTEx Consortium, 2015) and also for the neighboring
genes SUOX (thyroid), RAB5B (skeletal muscle) and AC034102.1
(skeletal muscle) (Supplementary Fig. 1). We explored the ENCODE
datasets for potential functional evidence of rs2292239 and found
ChIP-Seq based evidence of a CTCF (CCCTC-binding factor) tran-
scription factor (TF) binding site overlapping rs2292239 in multiple
ENCODE cell lines (Fig. 1). In total, we found ﬁve CTCF binding sites
within ERBB3, of which three had a conserved motif with knownTable 1
ERBB3/rs2292239 association with residual b-cell function and metabolic control. Results




Gender (male) 0.26 (0.10) 0.014
Age at diagnosis 0.05 (0.03) 0.051
Diabetes duration 0.19 (0.03) 1.31  1009
rs2292239 genotype model
GG (N ¼ 343) (39%; 1000 Genomes: 46%) Reference e
GT (N ¼ 406) (47%; 1000 Genomes: 41%) 0.05 (0.11) 0.67
TT (N ¼ 124) (14%; 1000 Genomes: 13%) 0.43 (0.16) 0.0077
rs2292239 recessive model
(TT vs. GG þ GT) 0.40 (0.15) 0.0067position weight matrices (PWMs) and DNase I footprint overlap
(Fig. 1). These conserved CTCF motif binding sites were located
within the promoter, 50UTR and the second exon of ERBB3 (Fig. 1).
Interestingly, in the HapMap3 CEU population rs2292239 was
found to be in strong LD (r2 ¼ 0.98) with rs3741499 and rs4759229
(Supplementary Fig. S2) and multiple lines of evidence based on
ENCODE regulatory features suggested functionality for these two
SNPs. For both SNPs, we observed enrichment for H3K4Me1 and
H3K27Ac histone marks, which are often found near active regu-
latory elements (Supplementary Fig. S3). Additionally, rs4759229
overlapped a DNase I hypersensitivity peak and both rs4759229
and rs3741499 overlapped ChIP-Seq peaks for several TFs in mul-
tiple ENCODE cell lines (Supplementary Fig. S3). Intriguingly, we
also found that rs4759229 lies within a known enhancer element
(chr12:56474601e56474862) based on FANTOM5 human active
enhancer atlas (Andersson et al., 2014). Taken together, these data
indicate that rs2292239, rs3741499, and rs4759229 might be
functional SNPs with regulatory implications.3.3. ERBB3 knockdown decreases basal and cytokine-induced
apoptosis
ERBB3 has been reported to be expressed and down-regulated in
response to pro-inﬂammatory cytokines in human islets at the
transcriptional level (Eizirik et al., 2012). Using western blotting we
conﬁrmed that ERBB3 is expressed and down-regulated by a
mixture of IL-1b, IFN-g and TNFa in human islets (p-value< 0.05,
Fig. 2A) and to IL-1bþ IFN-g in INS-1E cells (p-value< 0.05, Fig. 2B).
To investigate whether ERBB3 is involved in b-cell apoptosis, we
transfected INS-1E cells with non-targeting control siRNA or siRNA
against ERBB3 and examined the effect on cytokine-induced
apoptosis. To conﬁrm siRNA-mediated knockdown of ERBB3, the
protein expression of ERBB3 was examined. The ERBB3 expression
was reduced by 50% compared to cells transfected with control
siRNA (p-value< 0.05, Fig. 3A). Importantly, knockdown of ERBB3
decreased basal and cytokine-induced apoptosis compared to cells
transfected with control siRNA (p-value< 0.05, Fig. 3B). These
ﬁndings were supported by data showing decreased basal and
cytokine-induced caspase 3 and 7 activities, as assessed by caspase
activity assay (p-value< 0.05, Fig. 3C) and western blotting (p-
value< 0.05, Fig. 3D), suggesting that ERBB3 is required for
apoptosis in INS-1E cells.3.4. Non-coding RNA regulation of the ERBB3 locus
Non-coding RNAs (ncRNAs), e.g. lncRNAs and microRNAs
(miRNAs) are known to play an important role in regulation of gene
expression and their dysregulation has been associated with
various human diseases, including T1D (Guay and Regazzi, 2013;for IDAA1c and HbA1c in the linear regression model. The linear regression models
tly associated with IDAA1c and insulin dose.
HbA1c (%) Insulin dose (U/kg)
Estimate (S.E.) P-value Estimate (S.E.) P-value
0.09 (0.07) 0.19 0.0436 (0.02) 0.0077
0.001 (0.02) 0.95 0.0131 (0.004) 0.0021
0.04 (0.02) 0.052 0.0360 (0.004) 1.12  1013
Reference e Reference e
0.03 (0.08) 0.66 0.0037 (0.02) 0.83
0.26 (0.11) 0.020 0.042 (0.03) 0.093
0.24 (0.10) 0.019 0.040 (0.02) 0.083
Fig. 1. The genomic view and regulatory features of ERBB3 locus. The ERBB3 genomic view is adopted from the UCSC genome browser. Custom tracks were manually added for the
lncRNAs (depicted in red boxes) within ERBB3 locus (including 5 kb up/down-stream region). ChIP-Seq peak footprint region overlapping rs2292239 for CTCF transcription factor
binding region based on ENCODE ChIP-Seq experiments frommultiple cell lines (A549, GM19240, K562 and MCF-7) is highlighted separately. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
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within lncRNAs andmiRNAs have been linkedwith their expression
dysregulation (Guay and Regazzi, 2013; Mirza et al., 2014). We
identiﬁed ﬁve sense lncRNAs (NONHSAG011345, NONHSAG011346,
NONHSAG011347, NONHSAG011348 and NONHSAG011349) and one
antisense lncRNA (NONHSAG011350) intersecting the ERBB3 gene
(Fig. 1). However, NONHSAG011350 was excluded from further
analysis due to lack of evidence in Gencode annotations (Harrow
et al., 2012). Additionally, in 5 kb up/down-stream vicinity of
ERBB3, we found two lncRNAs (antisense NONHSAG011351 and
sense NONHSAG011352) intersecting the neighboring PA2G4 gene
(Fig. 1). All lncRNAs were found to be highly conserved based on
sequence alignments with three primates (chimpanzee, orangutan,
and macaque) (data not shown).
As SNPs within or up-/down-stream of a miRNA binding site can
alter the efﬁciency of miRNA binding and result in gene dysregu-
lation (Bruno et al., 2012), we explored CLIP-Seq datasets fromstarBase database v2.0 to identify miRNA binding sites within
ERBB3. We found eight miRNAs that target the ERBB3 30UTR of
which four were altered by up-/down-stream SNPs and indels
(Supplementary Table S2). However, none of our candidate SNPs
affected the miRNA binding.
3.5. Expression of ERBB3 and its associated lncRNAs
On comparing the expression proﬁles of the lncRNAswith ERBB3
across an array of 14 tissues using Human BodyMap (HBM) 2.0
RNAseq data, we observed distinct tissue-speciﬁc expression pat-
terns (Fig. 4A). The intronic/exonic lncRNAs (NONHSAG011345,
NONHSAG011346, NONHSAG011347, NONHSAG011348 and NON-
HSAG011349) exhibited relatively lower expression as compared to
the ERBB3. The lncRNAs intersecting PA2G4 (NONHSAG011351 and
NONHSAG011352) were found to be expressed across most of the
HBM tissues at similar levels as ERBB3. The expression proﬁles of
Fig. 2. Cytokine-mediated down-regulation of ERBB3 in human islets and INS-1E cells.
A) ERBB3 protein expression in human islets (n ¼ 3) left untreated or exposed to IL-1b,
IFN-g and TNFa for 48 or 72 h. B) ERBB3 protein expression in INS-1E cells (n ¼ 4) left
untreated or exposed to IL-1b and IFN-g for 24 h. Data are mean ± SD. ERBB3
expression was normalized to ponceau stainings (A) or a-Tubulin (B). *: p < 0.05.
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speciﬁcity. We next calculated the absolute pairwise correlations
(Pearson) between the expression levels of ERRB3 and its associated
lncRNAs (Supplementary Fig. S4). The highest correlations were
observed for intronic/exonic lncRNAs ranging from 0.57 to 0.91. The
correlations between the different lncRNAs ranged from 0.1 to 0.96.
Strong correlations were also observed between PA2G4 and its
intersecting lncRNAs NONHSAG011351 (r ¼ 0.8) and NON-
HSAG011352 (r ¼ 0.5) (Supplementary Fig. S5).
We examined the expression of ERBB3, CTCF, two intronic/exonic
lncRNAs (NONHSAG011348 and NONHSAG011349) and the antisense
lncRNA(NONHSAG011351) in fourhumanisletpreparations.Asshown
in Fig. 4B, ERBB3 and CTCFwere expressed at similar levels, whereas
the antisense lncRNA NONHSAG011351 was expressed at a higher
level. The intronic/exonic lncRNAs NONHSAG011348 and NON-
HSAG011349were not found to be expressed in the human islets.
Additionally, we measured the expression of lncRNAs NON-
HSAG011348, NONHSAG011349, NONHSAG011351 and ERBB3 in
HapMap cell lines (CEU population) carrying both heterozygous
and homozygous genotypes for SNPs rs2292239, rs3741499, and
rs4759229. The genotypic effect of these SNPs was computed based
on linear regression. Additionally, rs705708 was included in this
analysis based on results from our recent study which provided
regulatory evidence for rs705708 and its potential structure-
disruptive effects on NONHSAG011348 (Mirza et al., 2014). We
found that rs705708 had a cis-eQTL effect on both ERBB3 (p-
value < 0.05) and antisense lncRNA NONHSAG011351 (p-
value < 0.05). The GG genotype associated with lower expression of
ERBB3 and NONHSAG011351 (Fig. 5).
3.6. ERBB3 interacts with other T1D candidate genes
The EGFR signaling pathway has been well studied with respectto proteineprotein interactions. Although the interaction partners
for members of the ERBB family have been identiﬁed, their func-
tional roles are not well elucidated (Olayioye et al., 2000). We
retrieved all known proteineprotein interacting partners for ERBB3
using BioGRID (Stark et al., 2006); a database of protein and genetic
interactions based on high- and low-throughput experiments.
Overall, we found 88 physical associations for 61 interacting part-
ners for ERBB3 (Supplementary Fig. S6). Intriguingly, members of
the ERBB3 protein interactome included 6 bona-ﬁde T1D candidate
genes: ERBB2, GRB7, PA2G4, PTPN11, TENC1 and SH2B3, all known to
be regulated by pro-inﬂammatory cytokines (Eizirik et al., 2012). All
six genes were signiﬁcantly enriched within the ERBB3 interactome
(p-value ¼ 7.93e-04, binomial test). Noteworthy, two direct ERBB3
interactors PA2G4 and RNF41 share the same locus as ERBB3
(12q13.2), which suggests a regulatory interplay both at genetic
and protein levels.
4. Discussion
We show that genetic variation at the ERBB3 locus (rs2292239)
is associated with residual b-cell function, as assessed by IDAA1c,
and metabolic control in young children with T1D and disease
duration of at least 1 year. The TT genotype carriers had a better
residual b-cell function and a better metabolic control compared to
carriers of the GG þ GT genotype. A recent study by Torn C et al.
(T€orn et al., 2015) showed that the rs2292239 is also associated
with T1D speciﬁc autoantibody production. Autoantibody mea-
surements were not available in the present study, but we have
recently shown that rs2292239 is associated with multiple auto-
antibodies in longstanding T1D (Brorsson and Pociot, 2015). We
could not replicate the ﬁnding that rs2292239 was associated with
a lower age at onset (Hakonarson et al., 2008; Espino-Paisan et al.,
2011), most likely due to the fact that all children in our cohort were
diagnosed before the age of 11 years.
Although ERBB3 is a knownT1D candidate gene, the exact role of
ERBB3 in the pathogenesis of T1D remains largely obscure. Our data
show that ERBB3 is a novel regulator of b-cell apoptosis, i.e. ERBB3 is
down regulated by cytokines and knockdown of ERBB3 reduces
basal and cytokine-induced apoptosis. The PI3K/Akt pathway con-
stitutes an important general survival pathway including in b-cells
(Elghazi and Bernal-Mizrachi, 2009). As ERBB3 has been shown to
be associated with increased PI3K/Akt signaling (Lee et al., 2009,
2014a) and inhibition of Bak/Bax-mediated mitochondrial
apoptosis (Lee et al., 2014b), we hypothesize that the observed
protective effect on caspase 3/7 activation in INS-1E cells is due to
altered signaling via PI3K/Akt and/or mitochondrial apoptosis
signaling.
Previous studies suggest that ERBB3 contributes to disease
susceptibility by modulating antigen presenting cell function
(Wang et al., 2010) and autoimmunity (T€orn et al., 2015; Brorsson
and Pociot, 2015) indicating dual functional roles for ERBB3 dur-
ing the pathogenesis of T1D. The role of ERBB3 in T1D should be
examined further in cellular and animal models to gain insights
into the underlying molecular mechanisms. The ERBB3 locus ex-
hibits a relatively high degree of sequence variability (34 variations/
1 Kb) including SNPs, indels and other somatic mutations. Some of
these variations could be of functional signiﬁcance particularly
those that lie within the binding sites of known TFs. Generally,
functional TF binding is enriched at sites that are enriched in active
enhancers, regulatory elements harboring multiple TF binding
sites, and at sites with predicted higher binding afﬁnity (Andersson
et al., 2014; Cusanovich et al., 2014). Our analysis points towards
the functional signiﬁcance of SNPs rs2292239, rs3741499 and
rs4759229 based on the overlap with an active enhancer element,
CLIP-Seq peaks and DNase I footprints coverage, and the existence
Fig. 3. ERBB3 knockdown decreases basal and cytokine-induced apoptosis. INS-1E cells were transfected with control siRNA (siCTRL) or siRNA against ERBB3 (siERBB3) and then left
untreated or exposed to IL-1b and IFN-g for 24 h. A) ERBB3 protein expression (n ¼ 4). B) Apoptosis assessed by Cell Death Detection ELISA (n ¼ 5). C) Caspase-3/7 activity (n ¼ 3). D)
Cleaved caspase-3 protein expression (n ¼ 4). Data are mean and SD. Protein expression was not normalized. *: p < 0.05. **: p < 0.01.
S. Kaur et al. / Molecular and Cellular Endocrinology 419 (2016) 83e9188of multiple TF binding sites. Interestingly, rs2292239 also affects
the expression of ERBB3 and vicinity genes (SUOX and RAB5B) in
various tissues, suggesting an even more complex impact on dis-
ease susceptibility of this locus.
Evolutionary sequence conservation and distinct tissue-speciﬁc
expression patterns of ERBB3 locus associated lncRNAs indicates
their potential regulatory signiﬁcance. LncRNAs are in general
expressed in a tissue-speciﬁc manner and comparatively at lower
levels than their protein-coding counterparts (Derrien et al., 2012).
Furthermore, lncRNAs are known to regulate expression of both
proximal (cis) and distal (trans) protein-coding genes (Kornienko
et al., 2013). In particular, antisense lncRNAs are involved in tran-
scription regulationofprotein-codinggenes in cis (Wiluszet al., 2009;
Xu et al., 2011). Our results suggest potential regulatory roles of the
antisense lncRNA NONHSAG011351 on ERBB3 in human islets.CTCF is a ubiquitously expressed transcription factor that is
known to bind across the genome to chromatin boundaries, en-
hancers and gene promoters to regulate their transcriptional ac-
tivities. CTCF has been found to be up-regulated by high glucose and
insulin dosage in pancreatic islet b-cells where it mediates effects of
glucose on b-cell survival (Tsui et al., 2014). The presence of CTCF
binding sites in the 50UTR and introns of genes suggests a role for
CTCF in regulating transcriptional events downstream of the initi-
ation step (Chen et al., 2012). ChIP-Seq signals, together with the
DNase I footprints evidence indicates that CTCFmight have a pivotal
regulatory role in controlling ERBB3 expression by binding to its
promoter and intragenic (exon/intron) region through a canonical
conserved CTCF binding site motif. Nevertheless, our results war-
rant a systematic experimental follow-up to explore and validate
the potential regulatory roles of CTCF and the lncRNAs in
Fig. 4. Expression of ERBB3 and its associated lncRNAs in human islets and other tissues. (A) Heatmap and hierarchical clustering of expression levels (log 2 FPKM) for ERBB3 and its
associated lncRNAs across 14 tissues. (B) qPCR results for ERBB3, CTCF and antisense lncRNA NONHSAG011351 in human islets from four donors. The legend on the right represents
the four islet preparations.
Fig. 5. cis-eQTL effects of rs705708 on ERBB3 and NONHSAG011351 in HapMap CEU population. The expression proﬁles of ERBB3 and NONHSAG011351 based on qPCR in HapMap
(CEU) population. The cis-eQTLs were calculated for rs705708 based on linear regression.
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